Trump: All 50 states join Medicaid drug pricing model
TL/DR –
President Trump has announced a program in which all 50 states will join to provide Most Favored Nation pricing to some drugs within the Medicaid program. The aim is to bring the net price of selected drugs down to prices paid in other countries, which, according to the Trump administration, will save Medicaid billions on prescription drug costs. However, experts argue this is unclear due to the confidentiality of the deals’ content and express concern for the viability of this plan after Trump’s tenure.
“`html
Trump Administration Announces Drug Pricing Program Joined by All States
In an announcement on Friday, President Donald Trump revealed that all 50 states will participate in a program designed to offer Most Favored Nation pricing on certain Medicaid drugs. The initiative aims to reduce the net prices of these selected medications to match those in certain foreign countries.
Program Expected to Cut Medicaid Costs
The administration of President Trump believes this strategy, known as the Medicaid “GENEROUS” model, will result in billions in savings on prescription drugs. However, experts argue the extent of these savings is uncertain, given the non-disclosure of deal specifics.
A Political Strategy?
Amid the announcement, President Trump asserted that this move should secure a victory in the upcoming midterms. The statement was made in the Oval Office, with Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Mehmet Oz, and other officials in attendance.
Trump Battles Rising Healthcare Costs
As living cost concerns gain attention ahead of the November midterms, the Trump administration has been working towards affordability. Deals have been struck with pharmaceutical companies to bring U.S drug costs in line with those of other wealthy countries. This move has been met with criticism, with opponents arguing the administration lacks a comprehensive plan to tackle escalating health expenses, particularly following the expiration of Affordable Care Act subsidies.
In the previous year, Trump enacted a “Most Favored Nations” policy through an executive order. This policy commits the U.S to match the lowest drug prices globally.
Significant Savings Expected
According to a White House estimate in May, the deals with pharmaceutical companies could result in savings of approximately $529 billion over the following decade. Beneficiaries of Medicaid, a state and federal program for low-income individuals, may particularly benefit as lower prices could ease the strain on state budgets that support these programs.
Use of Savings
With the reduction in drug prices, states could have billions of dollars freed up for investment in other healthcare improvements, as stated by President Trump.
Cost-Savings Claims Under Scrutiny
The true savings remain uncertain due to the non-disclosure of deal specifics. This lack of transparency makes it challenging to independently verify the anticipated savings. The current administration’s approach has faced criticism, with a senior policy adviser at the Robert Wood Johnson Foundation, Kathy Hempstead, stating the need for more detailed data to justify the cost-savings claims.
Continuation of Price Cuts Uncertain
There are concerns about whether the price cuts will persist once the current administration concludes its term, as per Hempstead’s comments.
Call for Broader Benefit from Price Reductions
JD Hayworth, a spokesperson for the Pharmaceutical Reform Alliance and former Republican congressman, believes that while the announcement indicates significant progress, more needs to be done. He emphasized the need for lower drug prices for millions of Americans not enrolled in government healthcare programs.
The final cost of drugs for American patients can vary due to multiple factors such as competition and insurance coverage. Most Americans have coverage through their employment, individual insurance markets, or government programs such as Medicaid and Medicare, which partially insulate them from the costs.
“`
—
Read More US Economic News